Nature Communications (Aug 2022)

Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets

  • L. Mathur,
  • B. Szalai,
  • N. H. Du,
  • R. Utharala,
  • M. Ballinger,
  • J. J. M. Landry,
  • M. Ryckelynck,
  • V. Benes,
  • J. Saez-Rodriguez,
  • C. A. Merten

DOI
https://doi.org/10.1038/s41467-022-32197-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

Current screens to assess tumour drug resistance require a large amount of material, normally not available from patients. Here the authors report CombiSeq, a scalable microfluidic workflow to screen hundreds of drug combinations in picoliter-size droplets using transcriptome changes as a readout.